The predominant proteinaceous constituent of senile plaques observed in Alzheimer's disease is the amyloid peptide derived from amyloid precursor protein (APP) 1 (1). APP belongs to a larger gene family that includes the mammalian amyloid precursor like proteins 1 and 2 (APLP1 and -2) (2-5) as well as the Drosophila protein APPL (6) and the Caenorhabditis elegans protein APL-1 (7). Despite advances in understanding the biochemical and molecular properties and the regulation of the members of this gene family, their physiological function is not understood (1). APP knockout mice exhibit a weak phenotype with retarded neurite outgrowth (8), while APLP2 knockout mice appear phenotypically normal (9) or die at an early embryonic stage (10).
The predominant proteinaceous constituent of senile plaques observed in Alzheimer's disease is the amyloid peptide derived from amyloid precursor protein (APP) 1 (1) . APP belongs to a larger gene family that includes the mammalian amyloid precursor like proteins 1 and 2 (APLP1 and -2) (2-5) as well as the Drosophila protein APPL (6) and the Caenorhabditis elegans protein APL-1 (7) . Despite advances in understanding the biochemical and molecular properties and the regulation of the members of this gene family, their physiological function is not understood (1) . APP knockout mice exhibit a weak phenotype with retarded neurite outgrowth (8) , while APLP2 knockout mice appear phenotypically normal (9) or die at an early embryonic stage (10) .
APLP2 is ubiquitously expressed. Alternative splicing of APLP2 pre-mRNA generates at least four transcripts, two of which encode a Kunitz protease inhibitor domain (KPI) (3, 11) . Many structural features of APLP2 are reminiscent of a cell surface receptor. It is a large type I transmembrane protein whose sequence predicts a number of distinct domains; an N-terminal cysteine-rich domain exhibiting zinc, copper, and heparin binding activity (12) is followed by a very acidic region and, depending on the isoform, the KPI domain. All of these domains have their respective counterparts in APP. A very high degree of similarity between APLP2 and APP is found in the region following the KPI domain while the similarity decreases drastically in the ϳ100 amino acids (aa) preceding the transmembrane and cytoplasmic domains, which again exhibit a high sequence identity (3, 4, 13) . Biosynthesis and trafficking seems to follow initially the constitutive secretory pathway; upon synthesis and translocation into the ER, N-linked carbohydrates are added. Transport through the Golgi apparatus results in O-glycosylation and, depending on the splice variant, the addition of a chondroitin sulfate glycosaminoglycan (14, 15) . The ectodomain can be cleaved in a post-Golgi compartment or at the plasma membrane and is then secreted (15, 16) .
A similar pathway is followed by major histocompatibility complex (MHC) class I molecules, which bind peptides in the ER for presentation on the cell surface to cytotoxic T cells (17) . Completely assembled MHC I molecules consist of three subunits: an MHC encoded polymorphic transmembrane glycoprotein (heavy chain; HC) with an apparent molecular mass of ϳ45 kDa is noncovalently associated with a soluble light chain of 12 kDa, called ␤ 2 -microglobulin (␤ 2 m), and an 8 -10-aa-long peptide. Assembly of MHC I molecules occurs in the ER and is assisted by a number of chaperones (18 -20) . Initially, the free HC associates with the ER-resident chaperone calnexin, an integral membrane protein of ϳ90 kDa. In human cells, binding of ␤ 2 m to the HC triggers the dissociation from calnexin. The labile HC/␤ 2 m heterodimer is stabilized and further folded by other chaperones of the ER quality control machinery, such as calreticulin and ERp57, before being loaded with peptides (21) (22) (23) . The bulk of MHC I antigen-bound peptides arise from protein degradation within the cytosol. A specialized transporter associated with antigen processing (TAP) translocates these peptides into the ER (18, 20, 24) . In general, loading of MHC molecules with optimal peptides requires a physical association with TAP, which is mediated by tapasin, a 48-kDa protein encoded in the MHC (25, 26) . However, most of the accessory proteins are not absolutely essential for efficient cell surface expression of MHC I molecules, and different alleles differ in their requirement to interact with tapasin and TAP (27, 28) . Upon loading with peptide, class I heterotrimers dissociate from TAP and are efficiently exported to the cell surface (18) . Additional molecules like gp96 (29) , p100/110 (30), p100 (31) , or p62 may participate in the assembly process of MHC I molecules with peptides (22, 32) . However, their precise role and their temporal order of action are poorly defined.
Subversion of the MHC I assembly and antigen presentation pathway seems to be a common strategy employed by persistent viruses to escape immunosurveillance by their host (reviewed in Refs. [33] [34] [35] . For example, the human adenovirus (Ad) early region 3 (E3) glycoprotein E3/19K binds to MHC I molecules in the ER and inhibits transport of MHC I molecules to the cell surface (36, 37) . Consequently, MHC-restricted cytotoxic T cell lysis is severely suppressed (Refs. 33, 38, and 39 and references therein).
The function of the E3/19K protein is based on two activities; an HLA binding activity is combined with the ability to localize to the ER. This latter feature appears to require an ER retrieval motif in the cytoplasmic tail (40 -42) consisting of two lysines, KKXX or KXKXX, positioned either in Ϫ3 and Ϫ4 or Ϫ3 and Ϫ5 from the carboxyl terminus. Proteins containing these dilysine motifs can reach the cis-Golgi, where they are bound by specific cytosolic coat proteins that mediate retrograde transport to the ER (43, 44) .
Complex formation between MHC molecules and E3/19K is primarily mediated by their luminal domains (33, (45) (46) (47) (48) . Binding of MHC molecules to E3/19K is determined by their polymorphic ␣1 and ␣2 domains comprising the peptide binding pocket (46, 48) , while the HLA binding capacity of the Ad2 E3/19K protein is critically dependent on two intramolecular disulfide bonds within its luminal domain (47, 49 d . Polyclonal rabbit antisera AP tail and Kc were generated by immunization with the peptides CYENPTYKYLEQMQI and CKVMVHDPHSLA, corresponding to the C terminus of APLP2 and K d , respectively. Peptides CTKIIGSVS-KEEEEE and CADMDQFTASISET, representing amino acids 206 -219 and 570 -582 of APLP2, respectively, were used to raise antisera AP 206 and AP 570. The N-terminal cysteine was added for directed coupling to keyhole limpet hemocyanin or bovine serum albumin. Coupling and immunization was done essentially as described (47) . The polyclonal antibody APP tail raised against the 20 C-terminal amino acids of human APP (56) was a kind gift of V. Herzog (University of Bonn, Germany).
Purification of p100/110 -The source for large scale purification of p100/110 was 293.12K d 8 cells, which were grown on 510-cm 2 dishes, trypsinized, and centrifuged at 300 ϫ g. The pellet was frozen in liquid nitrogen and stored at Ϫ70°C until use. Approximately 9 ϫ 10 9 cells were used for purification. The protocol below is outlined for 2 ϫ 10 9 cells. Cells were lysed in 100 ml of lysis buffer (1% Nonidet P-40, 100 mM NaCl, 5 mM MgCl 2 , 20 mM Tris, pH 7.4). The cleared lysate was incubated with 1 mg of mAb 34-1-2 bound to 1 ml of protein A-Sepharose (Amersham Pharmacia Biotech, Uppsala, Sweden) for 3 h. Thereafter, the protein A pellet was washed three times with washing buffer B (0.2% Nonidet P-40, 10 mM Tris, pH 7.6, 0.15 M NaCl, 2 mM EDTA, pH 8.0), twice with buffer C (0.2% Nonidet P-40; 10 mM Tris, pH 7.6; 0.5 M NaCl; 2 mM EDTA, pH 8.0), and once with 10 mM Tris, pH 8.0. Bound antigens were eluted two times with 1.5 ml of 10 mM octyl glucoside, 0.2 M sodium acetate, pH 2.7. The supernatants were immediately neutralized, combined, and incubated with protein A beads for 1 h to adsorb most of the antibodies. Upon centrifugation, the supernatant was concentrated using a Centricon 100 device (Amicon). After the addition of 2 ml of 10 mM octyl glucoside, 5 mM Tris, pH 8.0, the material was concentrated again and stored at Ϫ70°C. Proteins contained in the eluate, including p100/110, antibody, E3/19K, K d , and ␤ 2 m, were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The gel was briefly stained with Coomassie Brilliant Blue and washed several times in water. The two bands, approximately 15 g each, were precisely excised, and gel slices were cut in pieces (about 1 ϫ 1 mm 2 ) and incubated for 16 h in water with frequent changes. The washed gel pieces were then immersed in 200 l of 100 mM ammonium hydrogen carbonate (pH 8.5) containing trypsin at an enzyme/protein mass ratio of approximately 1:5. Following incubation at 37°C for 8 h, the protein fragments produced were eluted from the gel by shaking the pieces twice for 3 h in an equal volume of 0.1% trifluoroacetic acid in water. Residual water was extracted from the gel matrix by treatment with acetonitrile. The concentrated eluates were extracted twice with isoamyl alcohol/heptane (1:4) to remove traces of SDS. Separation of the tryptic peptides was performed by reversed-phase high performance liquid chromatography on a Vydac 218TP5 column (1.6 ϫ 250 mm). Two peaks were selected from each elution diagram, and the material was subjected to gas phase sequence analysis. (36, 46) . Quantitative analysis of immunoprecipitates was carried out using a phosphor imager (Fujix Bas 1000; Fuji, Japan). Microsomes were prepared as described previously (30).
For sequential immunoprecipitation, the lysate was incubated for 30 min with the first antibody. Protein A-Sepharose was added, and the incubation continued for 45 min. This first immunoprecipitation was repeated, and the lysate was cleared from residual antibody by two sequential incubations with protein A-Sepharose for 45 min. Subsequently, a second specific antibody was added, and immunoprecipitation was performed as described before.
Brefeldin A (BFA) treatment was initiated 3 h before starvation of cells by replacing the medium with medium supplemented with 2.5 g/ml brefeldin A (Sigma, Deisenhofen, Germany). This concentration was kept throughout the starving and labeling period.
Endoglycosidase F Treatment-Endoglycosidase F treatment was carried out as described (30) except that 8 g/ml phenylmethylsulfonyl fluoride (Sigma) was included during the incubation.
Western Blotting-Immunoblotting was carried out as described (47, 57) . . Additional protein bands below the p100/110 bands are also detected. Bands corresponding to p100 and p110, respectively, were excised from a Coomassie Blue-stained gel and separately digested with trypsin. Fragments were separated by reversedphase high performance liquid chromatography, and from each digest two prominent peptide peaks were analyzed by microsequencing. Data base searches revealed a 100% identity of all four peptides to the human APLP2. Fig. 1B shows the putative amino acid sequence of the APLP2 protein (3) (4) (5) . Peptides sequenced from p100 and p110 are boxed. Peptide 4 was derived from p100, peptide 3 was derived from p110, and peptide 1/2 was obtained twice, once from p100 and once from the p110 digest.
RESULTS

Peptide Sequences from
Antibodies Directed to APLP2 Recognize Proteins with the Same Apparent Molecular Mass as That of p100/110 -Since the p100/110 preparation still contained minor contaminants, we could not exclude the possibility that these are the source of the sequenced peptides. Therefore, we tried to obtain independent evidence for the identity of APLP2 with p100/110. Polyclonal antisera were raised against three different peptides of human APLP2 (Fig. 1B, thick underline) . Antiserum AP tail is directed to the 14 C-terminal amino acids of the APLP2 cytoplasmic tail. This peptide was chosen, since antibodies against cytoplasmic portions of proteins are likely to react with the native protein. Antiserum AP 570 recognizes a peptide overlapping with P4 that was sequenced from p100 ( Fig. 1B) . Since murine and human APLP2 display an identity of 92.9% at the amino acid level, the animals used for immunization might be tolerant to these peptides. Therefore, a third peptide encompassing amino acids 206 -219 that is poorly conserved between mouse and human APLP2 (only 6 of 14 aa are identical) was selected to raise antiserum AP 206. All three sera were tested for their ability to immunoprecipitate APLP2 from detergent lysates. Antiserum AP 570 did not recognize APLP2 in detergent lysates, but it detected proteins with the same apparent molecular mass as APLP2 after SDS denaturation and/or Western blotting ( Fig. 3C; see below) . This indicates that the corresponding peptide is not accessible within the native molecule. Therefore, for most experiments, AP 206 and AP tail were used. Using metabolically labeled 293 cell lysates, both sera specifically immunoprecipitate proteins with apparent molecular masses of ϳ100, 110, and 210 -230 kDa ( Fig. 2A, lanes 2 and 7) . The specificity of the antisera was confirmed by showing that none of these proteins are precipitated with the respective preimmune sera (Fig. 2A, lanes 5 and 10) or upon the addition to the lysates of the respective peptides used for immunization ( Fig. 2A, lanes 3 and 4 and lanes 8 and 9) . The more diffuse band with an apparent molecular mass of ϳ220 kDa appears to represent a glycosaminoglycan (GAG)-modified form of human APLP2, since its molecular mass is reduced by cleavage with chondroitinase ABC (data not shown). A similar modification was noted previously for murine APLP2 (15) . We conclude that the peptide-specific antisera recognize APLP2.
Remarkably, the 100-and 110-kDa APLP2-specific protein species comigrate with p100/110 coprecipitated with K d from detergent lysates of 293.12K d 8 cells using the K d -specific antibody 34-1-2 ( Fig. 2A, lanes 1 and 6) . This indicates that both proteins are identical. However, the CS-GAG-modified form of APLP2 is not observed in 34-1-2 immunoprecipitates of 293.12K d 8 lysates and is hardly detectable using the rabbit antisera against APLP2 (see below).
The high degree of sequence similarity (71%) between human APLP2 and APP (11 of 14 amino acids of the AP tail peptide are identical), the appearance of two additional bands in the AP tail precipitate (open and closed arrowheads in Fig.  2A) , and the recently noted cross-reactivity of many "APPspecific" antibodies with APLP2 (13) prompted us to test whether our sera also cross-reacted with APP. To increase the APP-specific signal in 293 cells and to better be able to distinguish between APLP2 and APP, we generated a cell line (293APP) stably overexpressing the largest APP isoform, APP770. 293 and 293APP cells were labeled with [ 35 S]methionine, and lysates were subjected to immunoprecipitation with antisera raised against APLP2-and APP-specific peptides (Fig.  2B) . In 293APP cells, the APP serum recognizes two prominent proteins termed APP and APP*, which are also present in immunoprecipitates of AP tail but not in those of AP 206 (Fig.  2B, compare lane 6 with lanes 4 and 5) . Thus, the AP 206 serum is specific for APLP2, while the AP tail serum also recognizes APP. However, since the reactivity of AP 206 to APLP2 seemed to be significantly lower compared with that of AP tail (Fig. 2B,  lanes 1 and 2, or Fig. 2A, lanes 2 and 7) and coprecipitation of endogenous APP with AP tail was only marginal using detergent extracts of untransfected 293 cells (Fig. 2B, lane 1) , most subsequent experiments were performed with the AP tail serum.
To further substantiate our conclusion that APLP2 and p100/110 are identical, several biochemical properties of these molecules were compared. For example, the N-linked glycosy- lanes 2-4) . (lanes 1 and 6) . (Fig. 3A, lanes 1 and 6) or presence (Fig. 3A, lanes 2  and 5) of tunicamycin, an inhibitor of N-glycosylation. Second, immunoprecipitates of metabolically labeled cells were treated with endoglycosidase F, an enzyme that removes N-linked carbohydrates except for one N-acetylglucosamine (Fig. 3, lanes 3  and 4) . Both treatments reduced the molecular mass of p100/ 110 and APLP2 by ϳ3 kDa. Hence, N-glycosylation of p100/110 and APLP2 appears to be identical. A similar treatment of the K d protein, known to bear three N-linked carbohydrates, reduces its molecular mass by ϳ7.5 kDa (data not shown). Thus, only one (N541) of the two potential glycosylation sites (NQS and NPT) of APLP2 appears to be used. This can be explained by the nonfavorable sequence context of asparagine 287 (NXT, where X represents proline; Fig. 1B) , which may prevent its glycosylation (58) .
APLP2 is supposed to be a type I integral membrane protein (3, 4, 13) . Removing the putative cytoplasmic tail of the molecule should therefore reduce its apparent molecular mass by about 5.7 kDa. This was confirmed by incubating microsomes isolated from radiolabeled cells with or without proteinase K. APLP2 and p100/110 were immunoprecipitated using antibodies against APLP2 (AP tail and AP 206) and K d (34-1-2), respectively (Fig. 3B ). In line with the prediction made above, treatment with proteinase K abrogates recognition of APLP2 by the antiserum AP tail directed to the cytoplasmic tail of APLP2 (Fig. 3B, compare lanes 6 and 7) . (Fig. 3B, lane 2) is not observed in APLP2 precipitations. Therefore, this fragment is obviously derived from other proteins coprecipitating with K d molecules, most likely those appearing as a diffuse band with an apparent molecular mass of 50 -55 kDa. Taken together, we conclude that p100/110 and APLP2 have the same transmembrane orientation.
More direct evidence for the identity of p100/110 with APLP2 was obtained by reprecipitation (data not shown) and Western blotting of K d -associated material with APLP2-specific antisera. All three APLP2-specific sera recognized p100/110 coprecipitated by the K d -specific antibody 34-1-2 in Western blots (Fig. 3C and data not shown) . Moreover, V8 protease digestion of the lower and higher molecular forms of APLP2 results in peptide maps identical to those of p100 and p110, respectively (data not shown). Like p100 and p110, the APLP2 maps differ in the lower molecular weight range, confirming our previous interpretation that p100 and p110 and thus the two forms of APLP2 are derived from the same protein by differential splicing (30). Therefore, by all criteria tested (peptide sequencing, recognition by APLP2-specific antisera, biochemical properties, and V8 maps), p100/110 is identical to APLP2. lanes 1-3) and AP tail (lanes 4 -6) , respectively. Cells were either treated with 7 g/ml tunicamycin for 1 h prior to and during the labeling period (lanes 2 and 5) , or proteins were treated with 0.5 units of endoglycosidase F (Endo F) after immunoprecipitation (lanes 3 and 4) . As controls for the tunicamycin and endoglycosidase F treatment, cells and immunoprecipitates were mock-treated (lanes 1 and 6) . B, P100/110 and APLP2 have the same transmembrane orientation. 3 ϫ 10 7 293.12K lanes 1 and 3) . Immunoprecipitated (IP) material was separated by SDS-PAGE and transferred to a nylon membrane that was incubated with AP 570 (lane 1) and AP tail (lanes 2 and 3) . Upon incubation with alkaline phosphatase-coupled antibodies against rabbit IgG, phosphatase activity was developed by NBT/BCIP. (Fig. 4, lanes 6 and 7) and two additional antibody-clearing steps using protein A-Sepharose (not shown), only about one-third of the total amount of APLP2 protein remains and can be precipitated by the AP tail antibody (compare lane 8 with lanes 1 and 5). Vice versa, two successive rounds of immunoprecipitation with AP tail (Fig. 4, lanes 1 and  2) 4 with lanes 1 and 2) . The slightly reduced electrophoretic mobility of the two protein species coprecipitated in the murine cell lines is obviously a characteristic feature of murine APLP2, since the same differential mobility is also observed when APLP2 is directly precipitated using the AP tail serum (Fig. 5,  compare lanes 7 and 8 with lanes 5 and 6) . Antiserum AP 206 does not recognize murine APLP2 (Fig. 5, lanes 9 -12) (Fig. 6A, lanes 5-8) .
A Large Proportion of
In contrast, no APLP2-like proteins are visualized in cells that express K d in the absence of ␤ 2 m (Fig. 6A, lanes 3 and 4) . Instead, another protein of ϳ90 kDa is detected that comigrates with the ER chaperone calnexin, known to interact with incompletely assembled MHC molecules (data not shown). To promote the interaction of APLP2 with K d , we expressed E3/ 19K in these cells via infection with adenovirus type 2. Subsequently, K d was immunoprecipitated using antibodies directed to various portions of K d . Even after infection, no APLP2-specific proteins could be coprecipitated in lysates of ␤ 2 m Ϫ cells (Fig. 6B, FO-1K d -4, lanes 1-4) although they expressed E3/19K in similar amounts as ␤ 2 m ϩ cells (Fig. 6B, compare lanes 1 and  5) . Neither of the antibodies that recognized K d in the absence of ␤ 2 m (antiserum Kc, directed to the cytoplasmic tail of K d and detecting all K d molecules, or mAb SF1-1.1.1, which recognizes the ␣3 domain of K d ) coprecipitated APLP2, whereas the same antibodies readily precipitated APLP2 from ␤ 2 m ϩ cells (Fig.  6B, compare lanes 6 and 7 with lanes 2 and 3) (lanes 1 and 2) the Fig. 7A ). As shown in Fig. 7B , the amount of coprecipitated APLP2 is drastically increased in K d E3 immunoprecipitates compared with that seen when wildtype K d molecules are immunoprecipitated from extracts of E3/19K-negative cells (Fig. 7B, compare lanes 2 and 3) . Coprecipitation of APLP2 was as high as that observed when K d molecules were extracted from E3/19K ϩ cells (Fig. 7B, lane 1) . The slightly faster mobility of K d antibodies 34-1-2 and AP tail (Fig. 8) . In 293K d 2 cells, BFA treatment results in a profound increase (ϳ8-fold) in the association of two proteins with K d (Fig. 8, compare lanes 5 and 6) . These coprecipitating proteins seem to represent APLP2 species, since comigrating proteins are detected when APLP2 is precipitated directly (Fig. 8, lanes 2 and 4) or coprecipitated by 34-1-2 in 293.12K d 8 cells (Fig. 8, lane 8) 
DISCUSSION
In this report, we have shown by several criteria that p100/ 110, the previously discovered high molecular weight proteins associated with the MHC K d molecule in E3/19K ϩ cells, are identical to APLP2. First, peptide sequences derived from purified p100/110 proteins were identical to those in APLP2 (Fig.  1) . Second, three different antibodies raised against APLP2 precipitate proteins with the same apparent molecular mass as that of p100/110 and directly recognize p100/110 coprecipitated with K d in Western blots and sequential immunoprecipitations (Figs. 2 and 3 and data not shown). Third, biochemical properties of p100/110 and APLP2, such as N-glycosylation and transmembrane orientation, are identical (Fig. 3, A and B Which of the four APLP2 isoforms (APLP2-763, -751, -707, or -695) interact with K d molecules could not unequivocally be determined. In general, we only detect two primary protein species of 100 -105 and 110 -115 kDa, respectively. We previously showed that the different migration cannot be accounted for by differential N-linked glycosylation (Fig. 3A) or phosphorylation (30). Rather, the difference in apparent molecular mass of ϳ10 kDa suggests that these APLP2 species differ with regard to the presence of the KPI domain (calculated molecular mass: 6.6 kDa). Occasionally, each band was resolved as two species (data not shown), which may correspond to isoforms differing by the presence of the 12-aa peptide. Thus, the higher molecular weight band (p110) seems to represent isoforms 763 and 751, and the lower molecular weight band (p100) seems to represent isoforms 707 and 695. In isoforms APLP2-751 and APLP2-695, which lack the 12-aa insert, the sequence SGXG is preceded by acidic amino acids, a requirement for GAG modification (60) . Thus, only these forms are expected to undergo CS-GAG modification. Since K d proteins were found in association with CS-GAG-modified and unmodified APLP2 (Fig. 5) , we conclude that all four alternatively spliced APLP2 isoforms exhibit K d binding activity. In agreement with this hypothesis, GAG modification is greatly impaired in the presence of E3/19K, indicating that APLP2 is retained in the ER via its interaction with K d , whose transport is blocked by E3/19K (Fig. 5) .
At present, we know little about the structural features necessary for this interaction to occur. Despite the sequence similarity and the homologous domain structure of APP and APLP2, we could not detect any association with APP, even after overexpression of APP (data not shown). Therefore, structural features of APLP2 distinct from APP must be responsible for binding to K d . Candidate regions are the short stretch C-terminal to the KPI domain and the ϳ100 aa N-terminal to the putative membrane-spanning segment, including the A␤ domain, in which the APLP2 sequence is most divergent from that of APP (3) (4) (5) 11) . With regard to the structure of K d important for APLP2 binding, we show that N-linked carbohydrates are not essential for the interaction (Fig. 3A) . However, we demonstrate that APLP2 association with Previous data suggested a role of APLP2 during assembly or peptide loading of MHC I molecules. Several lines of evidence support this assumption. First, APLP2 and MHC I molecules exhibit an ubiquitous expression pattern and are both localized to the secretory compartment (3, 13, 18) . Second, interaction with APLP2 only occurs in the presence of ␤ 2 m (Fig. 6) . The same requirement exists for the association of empty class I molecules with TAP (18, 27, 62, 63) . Third, reminiscent of the dissociation of completely folded MHC molecules from TAP upon peptide loading (19, 20) , K d -binding peptides trigger the displacement of APLP2 from the complex with K d -␤ 2 m/E3/19K (30). Thus, conditions essential for the interaction of class I molecules with TAP are also crucial for complex formation between K d and APLP2. Intriguingly, E3/19K has been reported to bind to TAP (64) . Together, these data support the idea that APLP2 plays a role in peptide transfer to K d , e.g. in stabilization of empty ␣1/␣2 domains. Alternatively, APLP2 may bind during the peptide transfer step to MHC K d molecules, assisting its final folding or regulating by its KPI activity a putative peptide trimming protease and escorting the complex to the cell surface. This latter hypothesis is based on the known inhibition of various proteases by the KPI domains of APP and APLP2 (65) and the interaction of K d with GAGmodified APLP2, which implies that complexes exist beyond the ER. Whether complexes are present on the cell surface and, if so, whether these complexes serve a specific function remains to be investigated.
Interestingly, we routinely observe a prominent protein species of ϳ51-57 kDa coprecipitating with the K d -E3/19K-APLP2 complex ( Figs. 3B and 7; Ref. 30 ), which may be identical or related to the recently identified MHC I-associated ER-resident chaperone ERp57 with thiol-reductase activity (19, 20, 23, 66) . It has been proposed that this protein may be involved in oxidation of MHC I molecules or in trimming longer TAP translocated peptides. Both suggestions are compatible with its putative APLP2/K d association. It is also possible that the coprecipitated protein of ϳ55 kDa is related to p60 that binds peptides in the lumen of the ER (31) .
While a strong interaction of APLP2 was only observed with K d , weak interactions with HLA could be detected using more sensitive assays, such as immunoprecipitation of digitonin lysates combined with Western blotting (data not shown). At present, we do not know which feature of the K d molecule makes it more sensitive to complex formation with APLP2 than other MHC alleles. Transport of the K d molecule is rather slow, which may allow prolonged interaction. However, no Nonidet P-40 stable APLP2 complexes are detected with other MHC molecules having a similar export rate such as L d , D b , and HLA-C (data not shown). Interestingly, allelic differences exist for the association of MHC molecules with TAP and their dependence from tapasin for peptide loading (27, 28) . For example, HLA-B*2705 can be efficiently loaded with peptide in the absence of tapasin, while loading of HLA-B8 or HLA-B*4402 molecules is profoundly impaired under these conditions. Thus, differential requirements for the interaction of MHC alleles with proteins involved in MHC assembly and peptide loading do exist; therefore, differential requirements may also exist for complex formation of MHC molecules with APLP2.
The interaction of APLP2 with the MHC K d molecule described above is a novel activity of the APLP2 protein. Based on the structural similarity of APLP2 with APP, similar suggestions have been made as to the functions of both molecules, including a function as cell surface receptor (1, 67, 68) , as adhesion molecule involved in axogenesis (69) , as a growth factor for the secreted ectodomain (70), or as a DNA-binding protein with a role in DNA segregation during early embryonic development (5, 10) . Recently, it was realized that many antibodies raised against APP cross-react with APLP2 and vice versa (13) . Thus, a number of previous studies are difficult to interpret, since APP and APLP2 are not discriminated. In addition, the widely different functions suggested for APLP2 may be explained in part by the different systems employed, the number of isoforms present in the cells, and the difference in developmental stage (embryonic versus adult).
One hypothesis previously put forward suggests that APLP2 acts as cell surface receptor. In line with such a proposal, we observe complexes of K d with CS-GAG-modified APLP2 in E3/ 19K-negative cells (Fig. 5) , demonstrating that complexes do exist beyond the ER in the medial/trans-Golgi, where CS-GAG modification takes place, and possibly on the cell surface. To our knowledge, this is the first example of an APP family member forming physical complexes with immunologically relevant molecules. There are precedents for interactions between MHC molecules and other proteins seemingly unrelated to their antigen presentation function. For example, tetraspanin molecules like CD82 form complexes with MHC I molecules (71) . In addition, the murine cytomegalovirus protein gp34 has been shown to escort MHC molecules to the cell surface (72) . In both cases, it was speculated that these MHC I-binding proteins may modulate cytotoxic T cell or natural killer cell recognition. Determination of whether APLP2 influences the function of K d on the cell surface requires further investigation. Our studies reveal a novel, surprising mechanism for downregulation of APLP2 from the cell surface. By expression of E3/19K, which retains K d in the ER, the expression of an unrelated molecule, APLP2, is also affected. This mechanism is operating in the murine system, since we could show an interaction of K d with murine APLP2. Therefore, it is tempting to speculate that other (murine) viruses that target the antigen presentation pathway and retain class I molecules in the ER, such as murine cytomegalovirus (51), could also interfere with transport of APLP2. The functional consequences of an impaired cell surface expression await further clarification.
